Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.52 |
| ▸ | HPGD | P15428 | 6/20 | 0.52 |
| ▸ | HMGB1 | P09429 | 2/20 | 0.52 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | GGT1 | P19440 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6567084 | 1.00 | KDM4E (0.52) | KDM4EALDH1A1HSD17B10HPGDHMGB1 | |
| Sulfuric Acid SCHEMBL28096433 | 0.98 | KDM4E (0.50) | KDM4EALDH1A1HSD17B10HPGDHMGB1 | |
| SCHEMBL26647 | 0.98 | KDM4E (0.53) | KDM4EALDH1A1HSD17B10HPGDHMGB1 | |
| Water SCHEMBL3696220 | 0.96 | KDM4E (0.52) | KDM4EALDH1A1HSD17B10HPGDHMGB1 | |
| SCHEMBL20166760 | 0.96 | KDM4E (0.52) | KDM4EALDH1A1HSD17B10HPGDHMGB1 | |
| SCHEMBL3169153 | 0.96 | KDM4E (0.52) | KDM4EALDH1A1HSD17B10HPGDHMGB1 | |
| SCHEMBL7065758 | 0.96 | KDM4E (0.52) | KDM4EALDH1A1HSD17B10HPGDHMGB1 | |
| Ammonia Solution, Strong SCHEMBL10686252 | 0.96 | KDM4E (0.52) | KDM4EALDH1A1HSD17B10HPGDHMGB1 | |
| SCHEMBL8769958 | 0.96 | KDM4E (0.52) | KDM4EALDH1A1HSD17B10HPGDHMGB1 | |
| SCHEMBL6812015 | 0.96 | KDM4E (0.52) | KDM4EALDH1A1HSD17B10HPGDHMGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210077639-A1 | RADIOPHARMACEUTICAL PRODUCTS | GE HEALTHCARE LTD (GB) | 2021-03-18 | — | — | US | claimed |
| US-10328164-B2 | Radiopharmaceutical products | GE HEALTHCARE LIMITED (GB) | 2019-06-25 | — | — | US | claimed |
| CN-1331081-A | Tetraphosphine quatorphosphonium salt, its preparing process, and two-step tetraphosphine medicine kit and its application | UNIV BEIJING NORMAL (CN) | 2002-01-16 | — | — | CN | claimed |
| US-20260102523-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TETROFOSMIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | JUBILANT DRAXIMAGE INC (CA) | 2026-04-16 | — | — | US | disclosed |
| US-12440583-B2 | Pharmaceutical composition comprising tetrofosmin and pharmaceutically acceptable salts thereof | JUBILANT DRAXIMAGE, INC. (CA) | 2025-10-14 | — | — | US | disclosed |
| US-20250312364-A1 | METHODS FOR THE USE OF PSYCHEDELICS | TRYP THERAPEUTICS INC. (CA) | 2025-10-09 | — | — | US | disclosed |
| CN-118831183-A | Stabilized compositions of radionuclides and uses thereof | 瑞择生物公司 | 2024-10-25 | — | — | CN | disclosed |
| US-20240307420-A1 | IMPROVED METHODS FOR THE USE OF PSYCHEDELICS | TRYP THERAPEUTICS INC. (CA) | 2024-09-19 | — | — | US | disclosed |
| CN-118103078-A | Stabilized compositions of radionuclides and uses thereof | 瑞择生物公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-3592735-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF TETROFOSMIN OR ACID ADDITION SALT THEREOF | JUBILANT GENERICS LTD FORMERLY A DIVISION OF JUBILANT LIFE SCIENCES LTD (IN) | 2024-03-20 | — | — | EP | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-20090297442-A1 | RADIOPHARMACEUTICAL PRODUCTS | GE HEALTHCARE LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| EP-1345630-B1 | STABILISED RADIOPHARMACEUTICAL COMPOSITIONS | GE HEALTHCARE LTD (GB) | 2008-11-05 | — | — | EP | disclosed |
| EP-1824525-B1 | STABILISED 99mTC COMPOSITIONS | GE HEALTHCARE LTD (GB) | 2008-04-16 | — | — | EP | disclosed |
| EP-1824525-A1 | STABILISED 99mTC COMPOSITIONS | GE Healthcare Limited (GB) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006064175-A1 | STABILISED 99mTC COMPOSITIONS | GE HEALTHCARE LIMITED (GB) | 2006-06-22 | — | — | WO | disclosed |
| US-7052672-B2 | Stabilized radiopharmaceutical compositions | GE HEALTHCARE LIMITED (GB) | 2006-05-30 | — | — | US | disclosed |
| EP-1345630-A1 | STABILISED RADIOPHARMACEUTICAL COMPOSITIONS | GE Healthcare Limited (GB) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002053192-A1 | STABILISED RADIOPHARMACEUTICAL COMPOSITIONS | AMERSHAM PLC (GB) | 2002-07-11 | — | — | WO | disclosed |
| CN-1331081-A | Tetraphosphine quatorphosphonium salt, its preparing process, and two-step tetraphosphine medicine kit and its application | UNIV BEIJING NORMAL (CN) | 2002-01-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090297442-A1 | RADIOPHARMACEUTICAL PRODUCTS | MVD, TRHDE, EEF1E1 | KDM4E 1252/4885ALDH1A1 3402/4885HSD17B10 3747/4885 |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | KDM4E 2452/4885ALDH1A1 2174/4885HSD17B10 528/4885 |
| US-20210077639-A1 | RADIOPHARMACEUTICAL PRODUCTS | MVD, TRHDE, EEF1E1 | KDM4E 1252/4885ALDH1A1 3402/4885HSD17B10 3747/4885 |
| US-10328164-B2 | Radiopharmaceutical products | MVD, TRHDE, EEF1E1 | KDM4E 1252/4885ALDH1A1 3402/4885HSD17B10 3747/4885 |
| US-20260102523-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TETROFOSMIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TREH, CD68, THPO | KDM4E 3636/4885ALDH1A1 4433/4885HSD17B10 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.